Zacks Research Has Pessimistic Outlook of BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX - Free Report) - Stock analysts at Zacks Research dropped their Q3 2025 earnings estimates for shares of Becton, Dickinson and Company in a note issued to investors on Thursday, April 10th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $3.56 per share for the quarter, down from their prior forecast of $3.58. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company's Q4 2025 earnings at $4.13 EPS and Q2 2026 earnings at $3.78 EPS.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%.

Several other research analysts have also recently commented on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Barclays cut their target price on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday, April 7th. Finally, Piper Sandler raised their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $275.71.

Remove Ads

Becton, Dickinson and Company Trading Down 1.8 %

BDX traded down $3.69 during trading on Friday, reaching $202.02. The company had a trading volume of 2,567,831 shares, compared to its average volume of 1,691,214. The firm's 50-day simple moving average is $223.18 and its 200 day simple moving average is $229.56. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The company has a market cap of $58.01 billion, a price-to-earnings ratio of 33.56, a PEG ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12-month low of $193.03 and a 12-month high of $251.99.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDX. Principal Financial Group Inc. boosted its stake in Becton, Dickinson and Company by 1.5% during the third quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier's stock worth $284,429,000 after buying an additional 16,918 shares in the last quarter. Quantinno Capital Management LP boosted its position in shares of Becton, Dickinson and Company by 26.3% during the 3rd quarter. Quantinno Capital Management LP now owns 7,690 shares of the medical instruments supplier's stock valued at $1,854,000 after acquiring an additional 1,599 shares in the last quarter. Coldstream Capital Management Inc. increased its stake in Becton, Dickinson and Company by 13.3% in the third quarter. Coldstream Capital Management Inc. now owns 3,909 shares of the medical instruments supplier's stock valued at $938,000 after acquiring an additional 459 shares during the period. Toronto Dominion Bank raised its position in Becton, Dickinson and Company by 1.1% in the third quarter. Toronto Dominion Bank now owns 149,586 shares of the medical instruments supplier's stock worth $36,065,000 after purchasing an additional 1,681 shares in the last quarter. Finally, Arete Wealth Advisors LLC bought a new position in Becton, Dickinson and Company during the third quarter worth about $767,000. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the sale, the executive vice president now owns 7,411 shares in the company, valued at $1,666,808.01. This represents a 20.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bertram L. Scott sold 700 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now owns 36,033 shares of the company's stock, valued at approximately $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,675 shares of company stock valued at $1,057,182. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.06%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.